SG145723A1 - Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine - Google Patents
Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazineInfo
- Publication number
- SG145723A1 SG145723A1 SG200805893-5A SG2008058935A SG145723A1 SG 145723 A1 SG145723 A1 SG 145723A1 SG 2008058935 A SG2008058935 A SG 2008058935A SG 145723 A1 SG145723 A1 SG 145723A1
- Authority
- SG
- Singapore
- Prior art keywords
- phenylindan
- dimethylpiperazine
- chloro
- trans
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
- C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Trans-1(6-Chloro-3-Phenylindan-l.-Y1)-3,3-Dimethylpiperazine A compound 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-2,2-dimethylpiperazine and salts thereof, pharmaceutical compositions comprising the compound and salts, and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301180 | 2003-08-18 | ||
DKPA200301305 | 2003-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG145723A1 true SG145723A1 (en) | 2008-09-29 |
Family
ID=58707237
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200808521-9A SG148183A1 (en) | 2003-08-18 | 2004-08-18 | Succinate and malonate salt of trans-4-(1r,3s)-6-chloro-3-phenylindan-1-yl)- 1,2,2-trimethylpiperazine and the use as a medicament |
SG200805893-5A SG145723A1 (en) | 2003-08-18 | 2004-08-18 | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200808521-9A SG148183A1 (en) | 2003-08-18 | 2004-08-18 | Succinate and malonate salt of trans-4-(1r,3s)-6-chloro-3-phenylindan-1-yl)- 1,2,2-trimethylpiperazine and the use as a medicament |
Country Status (16)
Country | Link |
---|---|
KR (2) | KR101227789B1 (en) |
CN (1) | CN101935305B (en) |
AR (2) | AR045278A1 (en) |
AT (1) | ATE552247T1 (en) |
DK (1) | DK1658277T3 (en) |
EA (2) | EA014641B1 (en) |
ES (1) | ES2383369T3 (en) |
HK (2) | HK1096089A1 (en) |
IS (1) | IS8264A (en) |
ME (1) | MEP2408A (en) |
MY (2) | MY154535A (en) |
PT (1) | PT1658277E (en) |
RS (3) | RS20060083A (en) |
SG (2) | SG148183A1 (en) |
SI (1) | SI1658277T1 (en) |
TW (2) | TWI403505B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI453198B (en) * | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | Process for making the trans-1-( (1r , 3s)- 6-chloro - 3 -phenylindan-1- yl ) - 3 , 3 - dimethylpiperazine and salts thereof and for making 4 -((1r , 3s )-6- chloro- 3- phenylindan -1- yl )-1, 2 , 2 -trimethylpiperazine and salts thereof |
PL2720989T3 (en) | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
DK55192D0 (en) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindene derivatives |
-
2004
- 2004-08-18 MY MYPI20082882A patent/MY154535A/en unknown
- 2004-08-18 AT AT04762772T patent/ATE552247T1/en active
- 2004-08-18 TW TW099140932A patent/TWI403505B/en not_active IP Right Cessation
- 2004-08-18 KR KR1020067003177A patent/KR101227789B1/en active IP Right Grant
- 2004-08-18 SG SG200808521-9A patent/SG148183A1/en unknown
- 2004-08-18 DK DK04762772.4T patent/DK1658277T3/en active
- 2004-08-18 MY MYPI20043353A patent/MY149089A/en unknown
- 2004-08-18 RS YUP-2006/0083A patent/RS20060083A/en unknown
- 2004-08-18 SI SI200431885T patent/SI1658277T1/en unknown
- 2004-08-18 CN CN2010101632528A patent/CN101935305B/en not_active Expired - Fee Related
- 2004-08-18 SG SG200805893-5A patent/SG145723A1/en unknown
- 2004-08-18 PT PT04762772T patent/PT1658277E/en unknown
- 2004-08-18 RS YUP-2006/0121A patent/RS20060121A/en unknown
- 2004-08-18 AR ARP040102966A patent/AR045278A1/en not_active Application Discontinuation
- 2004-08-18 TW TW093124784A patent/TWI388550B/en not_active IP Right Cessation
- 2004-08-18 EA EA200600441A patent/EA014641B1/en not_active IP Right Cessation
- 2004-08-18 ES ES04762772T patent/ES2383369T3/en active Active
- 2004-08-18 AR ARP040102967A patent/AR045279A1/en not_active Application Discontinuation
- 2004-08-18 KR KR1020067003357A patent/KR20060066104A/en not_active Application Discontinuation
- 2004-08-18 ME MEP-24/08A patent/MEP2408A/en unknown
- 2004-08-18 EA EA200600443A patent/EA200600443A1/en unknown
- 2004-08-18 RS RS20060121A patent/RS53369B/en unknown
-
2006
- 2006-01-26 IS IS8264A patent/IS8264A/en unknown
-
2007
- 2007-03-21 HK HK07103032.7A patent/HK1096089A1/en not_active IP Right Cessation
-
2011
- 2011-06-29 HK HK11106689.0A patent/HK1152699A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA014641B1 (en) | 2010-12-30 |
ATE552247T1 (en) | 2012-04-15 |
HK1096089A1 (en) | 2007-05-25 |
MY154535A (en) | 2015-06-30 |
AR045278A1 (en) | 2005-10-19 |
KR101227789B1 (en) | 2013-01-30 |
IS8264A (en) | 2006-01-26 |
SI1658277T1 (en) | 2012-10-30 |
CN101935305A (en) | 2011-01-05 |
KR20060066094A (en) | 2006-06-15 |
RS20060121A (en) | 2008-09-29 |
ES2383369T3 (en) | 2012-06-20 |
AR045279A1 (en) | 2005-10-19 |
RS20060083A (en) | 2008-08-07 |
MY149089A (en) | 2013-07-15 |
TWI403505B (en) | 2013-08-01 |
SG148183A1 (en) | 2008-12-31 |
TW201111351A (en) | 2011-04-01 |
HK1152699A1 (en) | 2012-03-09 |
EA200600443A1 (en) | 2006-08-25 |
TW200519098A (en) | 2005-06-16 |
DK1658277T3 (en) | 2012-06-18 |
KR20060066104A (en) | 2006-06-15 |
PT1658277E (en) | 2012-05-25 |
MEP2408A (en) | 2010-02-10 |
RS53369B (en) | 2014-10-31 |
CN101935305B (en) | 2013-04-10 |
EA200600441A1 (en) | 2006-08-25 |
TWI388550B (en) | 2013-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061153L (en) | Trans-1- (6-chloro-3-phenylindan-1-yl) -3,3-dimethylpiperazine | |
MX2010004688A (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity. | |
AU2002344951A1 (en) | Substituted piperazine and diazepanes as histamine h3 receptor agonists | |
UY28360A1 (en) | NEW COMPOUNDS | |
TW200640890A (en) | Crystalline base of a pharmaceutical compound | |
NO20074593L (en) | Tartrate and malate salts of trans-1- (6-chloro-3-phenylindan-1-yl) -3,3-dimethylpiperazine | |
AU2003269364A1 (en) | Use of piperazine derivatives as ccr1 antagonists | |
SG155181A1 (en) | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | |
DK1511489T3 (en) | New pharmaceutical compositions containing flibanserin polymorph A | |
WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
WO2006064228A3 (en) | Thiazolopyramidine compounds for the modulation of chemokine receptor activity | |
SG145723A1 (en) | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine | |
AU2003260882A1 (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
UA89617C2 (en) | Succinate and malonate salt of trans 4-(1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and use thereof as a medicament | |
RS50523B (en) | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | |
TW200640891A (en) | Tartrate and malate salts of a pharmarceutical compound | |
AU2001244999A1 (en) | Naphthamide neurokinin antagonists for use as medicaments | |
WO2005113526A3 (en) | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one | |
AU2003294952A1 (en) | 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same | |
SE0301442D0 (en) | Diarylmethylidene piperidine derivatives, preparations therof and uses thereof | |
MY145425A (en) | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | |
AU2003214317A1 (en) | Use of a novel class of drugs for the treatment of parasitic diseases | |
DK1755583T3 (en) | Use of neboglamine for the treatment of schizophrenia | |
UA101341C2 (en) | Normal;heading 1;heading 2;heading 3;THERAPEUTIC USES OF COMPOUNDS HAVING COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY | |
ZA200503417B (en) | Use of piperazine sulfonic acid derivatives as CCR1 antagonists for the treatment of fibrosis, Alzheimer disease and other disorders |